Table 1.

Case report timeline with relevant data from the entire episode of care.

Timeline	Relevant data from the case presented
Day 1 to 6 (2nd to 7th January, 2022)	Symptoms: dysuria, fever accompanied by chills, lethargy, and mild lower abdominal pain.
Day 7 (8 January 2022)	Doctor consultation: the patient was found febrile with a 101°F body temperature.
Day 7 or 8 (8th or 9th January, 2022)	Blood test: revealed elevated blood glucose (10.3 mmol/L) with an elevated C-reactive protein (85 mg/ml). COVID tests: was found COVID negative by a RT PCR test.
Day 9 (10 January 2022)	Empirical treatment: was initiated with intravenous ceftriaxone (500 mg/8 h) to be continued for 7 days.
Day 15 (16 January 2022)	Patient response: The patient did not respond to the treatment, as symptoms persisted despite the administered therapy.
Day 16 (17 January 2022)	Urine culture, AST and WGS analysis: A urine sample was sent for urine culture and sensitivity testing and whole-genome sequencing (WGS).
Day 17 to 22 (18th to 23st January, 2022)	Turnaround time for tests: microbiological identification, AST, WGS and data analysis.
Day 23 (24 January)	Evidence-based treatment: Based on the results of the aforementioned tests, an evidence-based treatment was initiated, and the patient has been prescribed meropenem at a dosage of 500 mg/8 h for 14 days.
Day 30 (31 January)	Symptoms relieved: the case became afebrile with no complaints of dysuria and abdominal pain. Moreover, blood and Urine Culture tests were performed and found negative.
Day 36 (6 February 2022)	Patient recovery: the patient made a full recovery.
28 February 2022, 30 March 2022, 29 April 2022	Follow-up tests: the results of all three-monthly follow-up culture and sensitivity tests were negative, and no relapse of infection was detected.